Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis.

ABSTRACT:

Objective

To evaluate the safety profiles of EZH2-targeted inhibitors in cancer treatment, focusing on treatment-related adverse events (TRAEs) across various clinical trials.

Methods

We conducted a systematic review and meta-analysis using data from clinical trials involving EZH2 inhibitors reported up to May 31, 2024. Databases searched included PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.gov. Studies included were those involving patients treated with EZH2 inhibitors as monotherapy or in combination, specifically detailing the incidence of TRAEs. Data on all-grade TRAEs, grade 3 or higher TRAEs, and severe TRAEs were extracted and analyzed using random-effects models.

Results

Our systematic review and meta-analysis i

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC11781267 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature